France’s Pasteur Institute said on Monday it was ending development of a COVID-19 vaccine with US pharmaceutical company Merck after clinical trial results proved disappointing.
The partners announced a tie-up last May to develop a jab based on an existing measles vaccine, which was put into Phase 1 clinical trials in August.
“In these first human trials, the prospective vaccine was well tolerated but produced immune responses that were inferior to those observed in people who had recovered naturally and to those observed in the authorized vaccines,” a statement from Pasteur Institute said.
The announcement is a further blow for hopes of a French-led vaccine following recent news that leading national pharmaceutical company Sanofi is also struggling to bring its vaccine candidate to market.
Sanofi announced in December that its jab would be ready by the end of 2021 at best, and the group is now being encouraged by the government to help produce rival vaccines that have already been authorized for use in Europe.
These include products from German-American tie-up BioNTech/Pfizer and US pharma group Moderna.
Britain has also authorized the use of a vaccine developed by the University of Oxford and AstraZeneca, which is being assessed by European Union regulators.
The Pasteur Institute, named after pioneering scientist Louis Pasteur who developed a rabies vaccine in 1885, said it was working on two other COVID-19 vaccines which are not yet ready for clinical trials.
The decision to abandon the COVID-19 vaccine based on a measles jab “does not have any impact on the continuation of research by the Pasteur Institute into two other vaccine candidates which use different methodologies,” it said.